<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3598">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03060070</url>
  </required_header>
  <id_info>
    <org_study_id>321</org_study_id>
    <nct_id>NCT03060070</nct_id>
  </id_info>
  <brief_title>Ketamine Versus Dexmedetomidine With Local Anesthetic in TAP Block</brief_title>
  <official_title>Comparison of the Analgesic Effect of Ketamine Versus Dexmedetomidine Added to Local Anesthetic in TAP Block for Lower Abdominal Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South Egypt Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing the analgesic effects of ketamine and dexmedetomidine when added to local
      anesthetic in TAP block for postoperative analgesia after lower abdominal cancer surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative rescue morphine consumption</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>postoperative rescue morphine consumption</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Postoperative Analgesia</condition>
  <condition>Lower Abdominal Cancer</condition>
  <arm_group>
    <arm_group_label>control group,</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline in the same volume will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketamine group,</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ketamine in a dose of 0.5mg/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexmedetomidine in a dose of 1ug/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block</description>
    <arm_group_label>control group,</arm_group_label>
    <arm_group_label>dexmedetomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block</description>
    <arm_group_label>control group,</arm_group_label>
    <arm_group_label>ketamine group,</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>20ml of 0.25% bupivacaine will be injected in each side of the TAP block</description>
    <arm_group_label>ketamine group,</arm_group_label>
    <arm_group_label>dexmedetomidine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients ASA I and II to whom abdominal surgery for cancer will be conducted will
             be included in the study

        Exclusion Criteria:

          -  Coagulopathies

          -  ASA III or IV, patient refusal, sensitivity to the used drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed H Othman, MD</last_name>
    <phone>00201005098394</phone>
    <email>ahmadhothman@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>South Egypt Cancer Institute</name>
      <address>
        <city>Assiut</city>
        <state>Assiut University</state>
        <zip>171516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Othman, MD</last_name>
      <phone>00201005098394</phone>
      <email>ahmadhothman@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 17, 2017</lastchanged_date>
  <firstreceived_date>February 17, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed H Othman</investigator_full_name>
    <investigator_title>Associte professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abdominal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
